COPENHAGEN — Novo Nordisk shares climbed nearly 5% on Tuesday following the release of compelling new real-world data presented at the European Association for the Study of Diabetes (EASD) conference in Vienna. The Danish pharmaceutical leader unveiled results from the first head-to-head comparative study demonstrating that its blockbuster drug Ozempic significantly outperforms Eli Lilly’s dulaglutide in reducing major cardiovascular risks.
According to the study, patients treated with Ozempic experienced a 23% greater reduction in the combined risk of heart attack, stroke, and cardiovascular death compared to those on dulaglutide — a finding that reinforces Ozempic’s position as the gold standard in GLP-1 receptor agonist therapy, not only for weight management but increasingly for cardiovascular protection.
The data arrives at a pivotal moment for Novo Nordisk, as competition intensifies in the booming metabolic health sector. While Eli Lilly’s Mounjaro (tirzepatide) and upcoming Zepbound have captured headlines for superior weight loss efficacy, Novo’s latest findings underscore Ozempic’s entrenched clinical advantages — particularly in long-term cardiovascular outcomes, a critical metric for physicians and payers alike.
“Given the current valuation pressure on Novo shares, this data could catalyse a 5–10% upside,” noted Evan David Seigerman, senior analyst at BMO Capital Markets, in comments to Bloomberg. “It reaffirms Novo’s leadership in outcomes-based evidence — something that matters deeply in European and global healthcare systems.”
Investors responded swiftly, pushing Novo’s market cap higher and widening its lead over Eli Lilly in the European equity markets. Analysts suggest the study may also influence prescribing patterns and reimbursement decisions across the Nordics and EU, where health authorities prioritize therapies with proven cardiovascular benefit.
As the GLP-1 wars evolve beyond weight loss into chronic disease prevention, Novo Nordisk’s latest data positions it not just as a market leader — but as a standard-bearer for evidence-based, long-term patient outcomes.